logo
episode-header-image
Jul 2021
36m 59s

'Some Hope Is Better Than Having No Hope...

The New York Times
About this episode
When the F.D.A. approved the drug Aduhelm, the first Alzheimer’s treatment to receive the agency’s endorsement in almost two decades, it gave hope to many. But the decision was contentious; some experts say there’s not enough evidence that the treatment can address cognitive symptoms. What is the story behind this new drug? Guest: Pam Belluck, a health and ... Show More
Up next
Yesterday
The Autism Diagnosis Problem
<p>Once primarily limited to severely disabled people, autism began to be viewed as a spectrum that included children and adults far less impaired. Along the way, the disorder also became an identity, embraced by college graduates and even by some of the world’s most successful p ... Show More
32m 40s
Nov 23
Sunday Special: Wicked, Good?
<p>“Wicked” was one of the biggest movies of 2024. It was culturally ubiquitous, a box office smash and an Oscar nominee for Best Picture. Now, a year later, “Wicked: For Good” arrives in theaters to finish the tale of the complicated friendship between Glinda the Good Witch and ... Show More
51m 44s
Nov 22
'The Interview': John Green Knows That No One Really Loves You on the Internet
<p>The writer and YouTube star on trying to get back to the experiences that make us feel alive.</p><ul><li>Thoughts? Email us at <strong>theinterview@nytimes.com</strong></li><li>Watch our show on YouTube: <a href="https://www.youtube.com/@theinterviewpodcast"><strong>youtube.co ... Show More
44m 16s
Recommended Episodes
Dec 2022
Declining ALS Patients Are Waiting On The FDA's Next Move
For many years, pharmaceutical companies have tried and failed to find a treatment to slow symptoms of ALS–the debilitating, fatal illness also known as Lou Gehrig’s Disease. A potentially promising new drug from Biogen may offer some relief to those afflicted with an uncommon an ... Show More
25m 57s
Jun 2021
FDA Approves Aducanumab — A Controversial Drug For Alzheimer's
The FDA has approved a new drug for Alzheimer's. But a lot of experts are skeptical about whether the drug works. Rhitu Chatterjee talks with science correspondent Jon Hamilton about the controversial drug aducanumab and why the U.S. Food and Drug Administration approved it. For ... Show More
11m 52s
Nov 2021
Why Aduhelm, a new Alzheimer's treatment, isn't reaching many patients
Aduhelm, known generically as aducanumab, is the first drug to actually affect the underlying disease process associated with Alzheimer's. Yet sales have been limited, and the drug is reaching very few patients — at least so far. It's expensive, risky and likely doing little to i ... Show More
9m 45s
Feb 2024
Is ADHD being over-diagnosed?
An overwhelming demand for ADHD diagnoses has left the NHS struggling to keep up. What’s behind the rise?Content warning: This episode contains mentions of suicidal thoughts and eating disorders.This podcast was brought to you thanks to the support of readers of The Times and The ... Show More
31m 23s
Apr 2022
Dementia: Could lessons from Covid help find a cure?
<p>Just before the pandemic, the government promised a 'dementia moonshot' to blast us towards a dementia cure. What happened to it?</p><p>Today: former prime minister David Cameron and Sunday Times science editor Ben Spencer on Britain’s fastest growing disease, dementia.</p><p> ... Show More
30m 42s
Sep 2021
Fauci: Three doses of Covid-19 vaccine are likely needed for full protection
An official rollout of Covid-19 vaccine booster doses could begin within weeks, pending FDA authorization. The Biden administration has had internal conversations about scaling back the ambitious booster plan laid out by federal health officials. The Pfizer/BioNTech booster plan ... Show More
40m 15s